GlycosBio

Executive Summary

GlycosBio is a Houston-based biotechnology company leveraging enzymology and advanced lipid engineering to develop Activated Oil Systems—proprietary lipid formulations that enhance the delivery, bioavailability, and therapeutic performance of natural bioactive molecules. The company targets applications in personal care, nutrition, and therapeutics, with a specific focus on modulating the microbiome to treat conditions like dysbiosis. Founded in 2007, GlycosBio operates as a private entity with no disclosed funding rounds or pipeline visibility. Despite a long operating history, the company lacks publicly available data on clinical trials, partnerships, or revenue, which limits insight into its current traction or valuation. The activated oil technology could address growing demand for improved bioavailability in nutraceuticals and topical treatments, but commercialization progress remains unclear. Given the absence of recent milestones or financial disclosures, GlycosBio's near-term outlook is uncertain, though its technology platform may hold potential in the expanding microbiome modulation market.

Upcoming Catalysts (preview)

• 2026Partnership Announcement for Personal Care or Nutraceutical Applications30% success
• 2027Publication of Preclinical Data on Microbiome Modulation20% success
• 2027First Commercial Product Launch via Licensing Deal10% success